Core Laboratories (NYSE:CLB) Releases Q1 2026 Earnings Guidance

Core Laboratories (NYSE:CLB) updated its first quarter 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.110-0.150 for the period, compared to the consensus earnings per share estimate of 0.160. The company issued revenue guidance of $124.0 million-$130.0 million, compared to the consensus revenue estimate of $129.5 million.

Core Laboratories Stock Down 0.2%

Shares of Core Laboratories stock traded down $0.03 on Wednesday, reaching $19.61. 332,895 shares of the company were exchanged, compared to its average volume of 309,986. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.37 and a quick ratio of 1.76. The stock’s 50 day moving average price is $17.62 and its 200-day moving average price is $14.41. The company has a market cap of $913.04 million, a P/E ratio of 29.27, a price-to-earnings-growth ratio of 17.14 and a beta of 1.09. Core Laboratories has a 1-year low of $9.72 and a 1-year high of $20.36.

Core Laboratories (NYSE:CLB) last announced its earnings results on Wednesday, February 4th. The oil and gas company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.01. The business had revenue of $138.26 million for the quarter, compared to analyst estimates of $130.40 million. Core Laboratories had a net margin of 6.21% and a return on equity of 12.85%. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period last year, the firm posted $0.22 earnings per share. Core Laboratories has set its Q1 2026 guidance at 0.110-0.150 EPS. As a group, equities analysts forecast that Core Laboratories will post 0.96 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Core Laboratories in a research note on Monday, December 29th. Four analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $12.50.

Institutional Investors Weigh In On Core Laboratories

Institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Core Laboratories by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,893 shares of the oil and gas company’s stock worth $418,000 after buying an additional 1,170 shares in the last quarter. Captrust Financial Advisors lifted its position in shares of Core Laboratories by 11.8% during the 2nd quarter. Captrust Financial Advisors now owns 37,401 shares of the oil and gas company’s stock valued at $431,000 after acquiring an additional 3,936 shares during the period. Lido Advisors LLC purchased a new stake in shares of Core Laboratories during the 3rd quarter worth approximately $553,000. Balyasny Asset Management L.P. purchased a new stake in shares of Core Laboratories during the 2nd quarter worth approximately $586,000. Finally, Creative Planning boosted its position in Core Laboratories by 21.3% during the third quarter. Creative Planning now owns 68,564 shares of the oil and gas company’s stock worth $847,000 after purchasing an additional 12,050 shares in the last quarter. 97.81% of the stock is currently owned by hedge funds and other institutional investors.

Core Laboratories Company Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.